Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study

[1]  P. Bendahl,et al.  Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. , 2009, European urology.

[2]  J. Witjes.  Topic issue on new treatments in bladder cancer , 2009, World Journal of Urology.

[3]  J. Witjes,et al.  Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. , 2008, European urology.

[4]  J. Witjes,et al.  Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. , 2008, European urology.

[5]  A. Thwaini,et al.  Bladder contracture: review for intravesical bacillus Calmette-Guerin complication. , 2007, The Canadian journal of urology.

[6]  Ruifa Han,et al.  Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. , 2006, Urology.

[7]  H. Akaza,et al.  Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. , 2004, European urology.

[8]  T. Wilt,et al.  Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials , 2004, BJU international.

[9]  A. Böhle,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.

[10]  E. Kaasinen,et al.  Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. , 2002, European urology.

[11]  Y. Ohno,et al.  Randomized study of single early instillation of (2″R)‐4′‐O‐tetrahydropyranyl‐doxorubicin for a single superficial bladder carcinoma , 2002, Cancer.

[12]  Y. Ohashi,et al.  [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

[13]  Y. Ohashi,et al.  Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection , 1999, Cancer.

[14]  Richard Sylvester,et al.  Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer , 1999 .

[15]  A. Nabeeh,et al.  Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. , 1997, British journal of urology.

[16]  R Sylvester,et al.  A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. , 1993, The Journal of urology.

[17]  G. Barbalias,et al.  Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. , 1992, The Journal of urology.

[18]  P. Scardino,et al.  A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. , 1991, The New England journal of medicine.